<DOC>
	<DOCNO>NCT00289640</DOCNO>
	<brief_summary>The purpose clinical research study compare best overall response rate ( BORR ) ( per modify WHO criterion ) patient previously treat , therapy-refractory , -intolerant , Stage III ( unresectable ) Stage IV melanoma receive ipilimumab dos 0.3 , 3 , 10 mg/kg . The safety product also evaluate .</brief_summary>
	<brief_title>Study Ipilimumab ( MDX-010 ) Monotherapy Patients With Previously Treated Unresectable Stage III IV Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients previously treat , therapyrefractory intolerant , Stage III ( unresectable ) Stage IV melanoma</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Stage III ( unresectable )</keyword>
	<keyword>Stage IV melanoma</keyword>
</DOC>